#5: Celgene (CELG)
Celgene (CELG) is a specialized biotech company that focuses on treatments for small patient pools suffering from cancers and blood disorders. While there may not be a whole lot of candidates for Celgene’s drugs, the reality is that there aren’t a lot of alternatives out there and the treatments are very costly — and thus, high-margin products.
Revenue is set to grow 16% this year, and earnigns are expanding even faster with 60% growth expected by the end of fiscal 2013. And looking ahead to the New Year, Celgene announced a partnership with OncoMed (OMED) to work on new cancer drugs and stem cell therapies that could generate even more growth. With a plush product pipeline, tremendous earnings momentum and a pretty fair forward price-to-earnings of about 24, there is a good chance that we are only seeing the beginning of what Celgene has to offer.